News Center
Lizhu listed in the 2023 Top 20 ESG Competitiveness of Chinese Pharmaceutical Listed Companies and the Top 100 Innovative Pharmaceutical Enterprises in China.
Release time:
2023-11-07
Recently, the "2023 Top 20 ESG Competitiveness of Chinese Pharmaceutical Listed Companies (Mid-cap)" list was released, and Livzon Group stood out from over 300 participating companies due to its outstanding performance in ESG management, making the list for two consecutive years. At the same time, the "2023 Top 100 Chinese Pharmaceutical Innovation Enterprises" list, representing China's pharmaceutical innovation strength, was strongly released, with Livzon Group successfully making the list due to its excellent innovation and R&D capabilities.
This year, the ESG competitiveness evaluation of Chinese pharmaceutical listed companies covered all Hong Kong and A-share listed companies in the GICS primary industry classification - healthcare. After excluding companies that did not separately publish ESG/CSR reports, a total of 343 pharmaceutical listed companies entered the formal evaluation stage. The evaluation of this list consists of three dimensions: "ESG Transparency Assessment," "Substantive Issue Management Evaluation," and "ESG Controversy Events," comprehensively assessing the ESG management capabilities of listed companies in terms of ESG information disclosure quality, issue management practices, and risk control. The listed companies are the most representative pharmaceutical listed companies in domestic ESG management practices and serve as a learning benchmark for the transformation and upgrading of the domestic pharmaceutical industry to create sustainable industrial competitiveness.
For many years, under the leadership of Chairman Zhu Baoguo, Livzon Group has continuously maintained excellent performance, focusing on its own development while actively exploring the concepts of sustainable development and innovation. As of the 2023 fiscal year, Livzon Group has released ESG reports for seven consecutive years. The company actively responds to national calls, continuously improving the accessibility and affordability of pharmaceutical products; at the same time, it always adheres to a people-oriented approach, allowing every employee the opportunity to grow and create value in an equal, respectful, inclusive, and diverse work environment; it practices the concept of green operation, taking scientific and efficient measures to address major environmental issues such as climate change; and it actively undertakes social responsibility, engaging in public welfare activities such as chronic disease prevention and control, rural revitalization, and industrial assistance, encouraging employees to participate in diverse volunteer activities. In 2023, Livzon became the first company in the Chinese pharmaceutical industry to receive the highest MSCI ESG AAA rating.
In addition, the "2023 Top 100 Chinese Pharmaceutical Innovation Enterprises" list was released simultaneously in October 2023, with Livzon Group making the list due to its excellent innovation and R&D capabilities. The evaluation of this list is based on three dimensions: innovation foundation, innovation process, and innovation results, using four indicators for evaluation: the number of authorized patents, total patent citations, number of clinical trials, and the number of innovative drugs approved and launched. After data screening and integrated analysis, the final results were generated, making it one of the most credible and influential pharmaceutical innovation lists in the field of pharmaceutical innovation and investment.
Related Information